Insulin secretion pathway in pancreatic beta cell

Insulin release from pancreatic beta cells" refers to a **complex physiological process** rather than a single molecular target. The canonical mechanism is known as **glucose-stimulated insulin secretion (GSIS)**. In this process, increased blood glucose leads to uptake of glucose into the beta cells via glucose transporters such as GLUT2 or GLUT1/3. Inside the cell, glucose metabolism raises ATP levels, which closes ATP-sensitive potassium channels (K_ATP). This closure causes membrane depolarization and opens voltage-gated calcium channels; the resulting influx of calcium triggers exocytosis of preformed insulin granules into the bloodstream[1][5]. This pathway involves multiple molecular targets including K_ATP channel subunits Kir6.2/SUR1[4], voltage-gated calcium channels, SNARE proteins involved in vesicle fusion/exocytosis[2], and regulatory enzymes like glucokinase that sense intracellular glucose levels[7]. Pharmacologically relevant agents include sulfonylureas—which directly close K_ATP channels—and GLP‑1 receptor agonists that enhance GSIS through cAMP signaling pathways[1]. Because "insulin release from pancreatic beta cells" describes a **cellular function** rather than a discrete protein or gene product, it is not considered a therapeutic target itself but encompasses several validated drug targets within its mechanism. If you are seeking structured information for drug discovery or pharmacology databases focused on *molecular* targets rather than processes/pathways, you should refer instead to specific components such as "ATP-sensitive potassium channel subunit Kir6.2," "Sulfonylurea receptor 1," "Glucagon-like peptide 1 receptor," etc.[4][5]

Other names

Insulin release from pancreatic beta cellGlucose-stimulated insulin secretion (GSIS)Beta-cell insulin secretionPancreatic beta-cell exocytosis

Sulfonylureas close ATP-sensitive potassium channels to trigger depolarization and calcium influx, leading to insulin granule exocytosis[1][4].